Leukemia: all 5,475 studies
Page 29 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.
- Total Marrow and Lymphoid Irradiation and Chemotherapy for High-Risk Acute LeukemiaStatus unknownNCT03408223Not applicable
- Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute LeukemiaStatus unknownNCT03408210Not applicable
- A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid MalignanciesTerminatedNCT03404726Phase 1
- Honey or Olive Oil for Treating Oral Mucositis in Children and Adults With Leukemia Receiving Intensive ChemotherapyCompletedNCT03399331Phase 1
- A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT03398967Phase 1/2
- TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic AcidCompletedNCT03397173Phase 2
- CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic SyndromeCompletedNCT03393611Phase 1
- Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid LeukemiaCompletedNCT03389724Phase 3
- Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCTCompletedNCT03389035Phase 1/2
- Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)CompletedNCT03388749Phase 1/2
- Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 MutationsStatus unknownNCT03381781Phase 2
- Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML PatientsTerminatedNCT03381118Phase 2
- Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT03374137
- Psychological Intervention Mobile App for Patients With AMLCompletedNCT03372291Not applicable
- Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic LymphomaWithdrawnNCT03370185Phase 2
- Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic LeukemiaCompletedNCT03367299Phase 2
- QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AMLWithdrawnNCT03365661Phase 2
- A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) CancerTerminatedNCT03360006Phase 1
- DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast ExcessStatus unknownNCT03356080Phase 2
- Sleep Assessment in CMLStatus unknownNCT03353558
- Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.CompletedNCT03350152
- Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive AspergillosisCompletedNCT03349931
- Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHLCompletedNCT03349281Phase 1
- Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid LeukemiaStatus unknownNCT03348033Phase 1/2
- Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT03347994Phase 1
- This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With VenetoclaxWithdrawnNCT03343678Phase 1
- Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic LeukemiaStatus unknownNCT03339700Phase 2
- Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2CompletedNCT03338348Phase 2
- Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional BiomarkersStatus unknownNCT03337516Not applicable
- Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and NeutropeniaCompletedNCT03333005Phase 1
- Efficacy and Safety of Nilotinib in CML-CPCompletedNCT03332511Phase 4
- Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic LeukemiaStatus unknownNCT03331211
- A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ LeukemiaActive, not recruitingNCT03330691Phase 1
- Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/LymphomaCompletedNCT03328104Phase 1
- C-CAR011 Treatment in Subjects With ALL After HSCTStatus unknownNCT03327285Not applicable
- MB-CART19.1 in Patients With R/R ALLStatus unknownNCT03321123Phase 2
- Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALLActive, not recruitingNCT03319901Phase 1/2
- Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaStatus unknownNCT03318770
- Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic LeukemiaStatus unknownNCT03318419Phase 2
- Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient InductionCompletedNCT03316456
- Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.CompletedNCT03311815
- Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical PracticeCompletedNCT03310190
- NLA101 in Adults Receiving High Dose Chemotherapy for AMLTerminatedNCT03301597Phase 2
- Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantActive, not recruitingNCT03301168Phase 1/2
- CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and LymphomaStatus unknownNCT03298828Phase 1
- A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction ChemotherapyCompletedNCT03298516Phase 1
- Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After AllotransplantStatus unknownNCT03297528Phase 2
- Clinical Application of Novel Panels for Early Precision Diagnosis and Relapse Prediction in High-risk LeukemiaCompletedNCT03297476
- An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT03289182
- Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®Status unknownNCT03287128
- Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life ConditionActive, not recruitingNCT03284593
- Cd11b and Cd56 as Prognostic Markers in Acute Myeloid LeukemiaStatus unknownNCT03283228
- Effect of Prevention Education in Caries Formation in Pediatric Patients With LeukemiaTerminatedNCT03281746Not applicable
- Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With OfatumumabStatus unknownNCT03280160Phase 2
- Hematotoxicity in Acute Lymphoblastic Leukemia Children in Maintenance Phase TherapyCompletedNCT03279900
- Dependence Receptors and LeukemiaStatus unknownNCT03278145
- Expression of TET1 Gene in Acute LeukaemiaStatus unknownNCT03267485
- DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic LeukemiaTerminatedNCT03265717Phase 2
- A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma SubjectsStatus unknownNCT03265106Phase 1/2
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.Status unknownNCT03263208Phase 1/2
- Effect of Pharmacogenetics on Imatinib Plasma Level and ResponseCompletedNCT03262974
- Anti-CD22 CAR-T Cell Therapy Targeting B Cell MalignanciesStatus unknownNCT03262298Phase 1/2
- Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 StudyStatus unknownNCT03260101
- Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCTStatus unknownNCT03256071Phase 2/3
- Hematotoxicity in Maintenance Therapy of Children With Acute Lymphoblastic LeukemiaCompletedNCT03255668
- TKI Discontinuation in CML Patients of ChinaStatus unknownNCT03251352
- New Markers for Minimal Residual Disease in Acute Lymphoblastic LeukemiaStatus unknownNCT03249636
- Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 MutationApproved for marketingNCT03245424
- A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and LymphomaCompletedNCT03244306Phase 1
- The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous LeukaemiaStatus unknownNCT03241199Phase 2
- Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4logStatus unknownNCT03239886Not applicable
- A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCLCompletedNCT03239392Phase 1/2
- A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory MalignanciesCompletedNCT03236857Phase 1
- Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic SyndromesStatus unknownNCT03235973Phase 1
- Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid LeukemiaCompletedNCT03234985
- Laboratory Studies Into the Pathology of LeukaemiaStatus unknownNCT03233763
- Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid LeukemiaStatus unknownNCT03228303Early Phase 1
- A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 AberrationsActive, not recruitingNCT03226301Phase 2
- Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.TerminatedNCT03217838Phase 1
- Low-dose Dasatinib as First-line Treatment for Chronic Myeloid LeukemiaStatus unknownNCT03216070Phase 4
- Myeloid Derived Suppressor Cells and Chronic Myeloid LeukemiaStatus unknownNCT03214718Not applicable
- Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)WithdrawnNCT03207542Phase 2
- iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)WithdrawnNCT03207334Phase 2
- Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic LeukemiaCompletedNCT03204916
- Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid LeukaemiaCompletedNCT03197714Phase 1
- Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous LineageCompletedNCT03194932Phase 1
- Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03194685Phase 1
- A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell MalignanciesStatus unknownNCT03191773Phase 1/2
- A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCTStatus unknownNCT03190733Phase 4
- Quality of Life in Children With CancerCompletedNCT03190499
- Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic LeukaemiaWithdrawnNCT03187691Phase 2
- Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ LeukemiaActive, not recruitingNCT03186118Phase 1
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22Status unknownNCT03185494Phase 1/2
- Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid LeukemiaStatus unknownNCT03181815Phase 2
- A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic LymphomaCompletedNCT03181126Phase 1
- A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCTCompletedNCT03176849Phase 4
- The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid LeukemiaStatus unknownNCT03173612Not applicable
- A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and LymphomaStatus unknownNCT03166878Phase 1/2
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2